Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15474468 | 0.97 | RIPK1 (0.50) | RIPK1CYP2C19TBXAS1CNR1CNR2 | |
| SCHEMBL27741741 | 0.95 | RIPK1 (0.49) | RIPK1CYP2C19TBXAS1CNR1CNR2 | |
| SCHEMBL27360178 | 0.86 | PPARA (0.48) | RIPK1CYP2C19TBXAS1CNR1CNR2 | |
| SCHEMBL11746883 | 0.84 | FFAR4 (0.46) | TBXAS1 | |
| SCHEMBL14360139 | 0.83 | TBXAS1 (0.60) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| SCHEMBL337193 | 0.82 | RIPK1 (0.46) | RIPK1CYP2C19TBXAS1CNR1CNR2 | |
| SCHEMBL337192 | 0.82 | RIPK1 (0.46) | RIPK1CYP2C19TBXAS1CNR1CNR2 | |
| SCHEMBL455432 | 0.81 | POLB (0.53) | CYP2C19TBXAS1CNR2SMN1; SMN2POLB | |
| Ammonia Solution, Strong SCHEMBL28556745 | 0.81 | TBXAS1 (0.59) | CYP2C19TBXAS1CYP2D6SRCPOLB | |
| Ammonia Solution, Strong SCHEMBL28562956 | 0.81 | TBXAS1 (0.59) | CYP2C19TBXAS1CYP2D6SRCPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015907-A1 | Furopyridine compounds and uses thereof | CYP3A5, QDPR, DPYD | RIPK1 4668/4885CYP2C19 5/4885TBXAS1 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.